Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Dominik Andreas BarthStefanie StanzerJasmin SpiegelbergThomas BauernhoferGudrun AbsengerFlorian PoschRainer LippMichael HalmJoanna SzkanderaMarija BalicArmin GergerMaria A SmolleGeorg C HuttererChristiane KlecPhilipp J JostJulia KarglMartin StradnerMartin PichlerPublished in: Cancer medicine (2022)
Autoantibodies at treatment initiation or induction after 8-12 weeks of ICI treatment are not associated with treatment efficacy as indicated by DCR, ORR, and PFS or higher grade irAEs.